Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Skyler V HendrixDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-0644-6519
Yassin MreyoudDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-2747-3652
Michael E McNehlanDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.
Asya SmirnovDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-4767-1680
Sthefany M ChavezDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-5887-8826
Brian HieRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
Megan M ChamberlandDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.ORCID 0000-0001-7311-0663
Tara R BradstreetDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-4073-6130
Ashlee M WebberDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-2067-5553
Darren KreamalmeyerDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.
Reshma TanejaDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.ORCID 0000-0001-6214-6177
Bryan D BrysonRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.ORCID 0000-0003-1716-6712
Brian T EdelsonDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0003-2856-7650
Christina L StallingsDepartment of Molecular Microbiology, Center for Women's Infectious Disease Research, Washington, University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-2747-5618
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8M
TRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4M
Infectious Diseases/Basic Microbial Pathogenic MechanismsT32AI007172 · NIAID · WASHINGTON UNIVERSITY · PI Daniel E. Goldberg, JENNIFER A PHILIPS · 1985 to 2026
$13.0M
Training Program in Cellular and Molecular BiologyT32GM139774 · NIGMS · WASHINGTON UNIVERSITY · PI HEATHER L TRUE-KROB · 2021 to 2026
$6.7M
Regulation of Immune Responses to Mycobacterium tuberculosis InfectionR01AI132653 · NIAID · WASHINGTON UNIVERSITY · PI EDELSON, BRIAN TODD, STALLINGS, CHRISTINA LEIGH · 2018 to 2022
$3.0M
EQUIPMENT FOR ELECTRON MICROPROBE ANALYSISS10RR002345 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DI BONA, DONALD R · 1985 to 1985
–
Burroughs Wellcome Fund (BWF) 1016714HHS | NIH | National Center for Research Resources (NCRR) UL1TR002345HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI132653HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM007067HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID) AI007172NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NIAID NIH HHS R01 AI132653NIAID NIH HHS T32 AI007172NIGMS NIH HHS T32 GM007067NIGMS NIH HHS T32 GM007200NIGMS NIH HHS T32 GM139774
6 · The paper itself
Abstract
Better understanding of the host responses to Mycobacterium tuberculosis infections is required to prevent tuberculosis and develop new therapeutic interventions. The host transcription factor BHLHE40 is essential for controlling M. tuberculosis infection, in part by repressing Il10 expression, where excess IL-10 contributes to the early susceptibility of Bhlhe40-/- mice to M. tuberculosis infection. Deletion of Bhlhe40 in lung macrophages and dendritic cells is sufficient to increase the susceptibility of mice to M. tuberculosis infection, but how BHLHE40 impacts macrophage and dendritic cell responses to M. tuberculosis is unknown. In this study, we report that BHLHE40 is required in myeloid cells exposed to GM-CSF, an abundant cytokine in the lung, to promote the expression of genes associated with a proinflammatory state and better control of M. tuberculosis infection. Loss of Bhlhe40 expression in murine bone marrow-derived myeloid cells cultured in the presence of GM-CSF results in lower levels of proinflammatory associated signaling molecules IL-1β, IL-6, IL-12, TNF-α, inducible NO synthase, IL-2, KC, and RANTES, as well as higher levels of the anti-inflammatory-associated molecules MCP-1 and IL-10 following exposure to heat-killed M. tuberculosis. Deletion of Il10 in Bhlhe40-/- myeloid cells restored some, but not all, proinflammatory signals, demonstrating that BHLHE40 promotes proinflammatory responses via both IL-10-dependent and -independent mechanisms. In addition, we show that macrophages and neutrophils within the lungs of M. tuberculosis-infected Bhlhe40-/- mice exhibit defects in inducible NO synthase production compared with infected wild-type mice, supporting that BHLHE40 promotes proinflammatory responses in innate immune cells, which may contribute to the essential role for BHLHE40 during M. tuberculosis infection in vivo.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
BHLHE40 Regulates Myeloid Cell Polarization through IL-10-Dependent and -Independent Mechanisms. · full record | Socratic